Europe Hyaluronidase Market Size & Outlook, 2030

Revenue, 2023 (US$M)

$258.4

Forecast, 2030 (US$M)

$455.6

CAGR, 2024 - 2030

8.4%

Report Coverage

Europe

Europe hyaluronidase market, 2018-2030 (US$M)

Related Markets

Global Hyaluronidase Industry Outlook

North America Hyaluronidase Market Outlook

Asia Pacific Hyaluronidase Market Outlook

Latin America Hyaluronidase Market Outlook

MEA Hyaluronidase Market Outlook

Europe hyaluronidase market highlights

The Europe hyaluronidase market generated a revenue of USD 258.4 million in 2023.
The market is expected to grow at a CAGR of 8.4% from 2024 to 2030.
In terms of segment, animal-derived hyaluronidase was the largest revenue generating type in 2023.
Animal-derived Hyaluronidase is the most lucrative type segment registering the fastest growth during the forecast period.

Europe data book summary

Market revenue in 2023	USD 258.4 million
Market revenue in 2030	USD 455.6 million
Growth rate	8.4% (CAGR from 2023 to 2030)
Largest segment	Animal-derived hyaluronidase
Fastest growing segment	Animal-derived Hyaluronidase
Historical data covered	2018 - 2022
Base year for estimation	2023
Forecast period covered	2024 - 2030
Quantitative units	Revenue in USD million
Market segmentation	Animal-derived Hyaluronidase
Key market players worldwide	Bausch & Lomb Corp, The Cooper Companies Inc, Sun Pharmaceutical Industries, STEMCELL Technologies, Amphastar Pharmaceuticals Inc, Prima Pharm, Halozyme Therapeutics, Shreya Life Sciences

Other key industry trends

In terms of revenue, Europe region accounted for 26.2% of the global hyaluronidase market in 2023.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
Asia Pacific is the fastest growing regional market and is projected to reach USD 382.0 million by 2030.

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Hyaluronidase Market Scope

Hyaluronidase market segmentation & scope

Type

Animal-derived Hyaluronidase

Synthetic Hyaluronidase

Application

Dermatology

Chemotherapy

Ophthalmology

Plastic Surgery

Others

Regions

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Countries

U.S.

Canada

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Japan

China

India

Australia

South Korea

Thailand

Mexico

Brazil

South Africa

Saudi Arabia

Argentina

UAE

Kuwait

Hyaluronidase Market Companies

Name	Profile	# Employees	HQ	Website

Europe hyaluronidase market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hyaluronidase market will help companies and investors design strategic landscapes.

Animal-derived hyaluronidase was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Europe hyaluronidase market based on animal-derived hyaluronidase covering the revenue growth of each sub-segment from 2018 to 2030.

Rising incorporation of hyaluronidase in various drug delivery technologies has encouraged local manufacturers to invest in the development of novel hyaluronidase products. For instance, in March 2019, ALTEOGEN, Inc. received a patent for its subcutaneous formulation of trastuzumab biosimilar that incorporates human hyaluronidase for the treatment of breast cancer.

Alteogen announced that it has plans to file additional Patent Cooperation Treaty and patent applications in 12 countries including Europe. This patent application is expected to allow the company to monopolize the European market for subcutaneous version of biosimilar trastuzumab.

Moreover, guidelines issued by multiple private and public entities for the use of hyaluronidase in esthetic procedures ensure efficient regulation and management of hyaluronidase in Europe.

Reasons to subscribe to Europe hyaluronidase market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe hyaluronidase market databook

Our clientele includes a mix of hyaluronidase market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe hyaluronidase market , including forecasts for subscribers. This continent databook contains high-level insights into Europe hyaluronidase market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list